| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
POM-1 is an inhibitor of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases). Reported Ki values are: 2.58 μM for NTPDase1, 28.8 μM for NTPDase2, and 3.26 μM for NTPDase3. [1]
|
|---|---|
| ln Vitro |
In cerebellar slices, POM-1 (100 μM) significantly inhibits the breakdown of extracellular ATP (100 μM) by ~57.4%, which is more effective than the standard inhibitor ARL 67156 (13.9% inhibition). At a lower ATP concentration (25 μM), the inhibition by POM-1 is ~68%. HPLC analysis confirms that POM-1 acts at the first step of the ATP breakdown cascade (ATP to ADP), reducing the accumulation of downstream metabolites (ADP, AMP, and adenosine). [1]
Application of POM-1 (100 μM) also inhibits glutamatergic synaptic transmission at parallel fibre-Purkinje cell synapses, climbing fibre-Purkinje cell synapses in the cerebellum, and Schaffer collateral-CA1 synapses in the hippocampus. This inhibitory effect is independent of NTPDase inhibition and P2 receptor activation, and is characterized by a reduction in excitatory postsynaptic potential (EPSP) amplitude, an increase in paired-pulse ratio, and a decrease in presynaptic fiber volley amplitude. [1] |
| ln Vivo |
In animal models of ischemia, POM-1 has been found to increase cardiac infarct size following ischemia and abolish the protective effects of cardiac and renal ischemic preconditioning. These effects are attributed to reduced breakdown of ATP to cytoprotective adenosine. [1]
|
| Enzyme Assay |
The inhibitory efficacy of POM-1 on extracellular ATP breakdown was assessed using a malachite green phosphate assay. Cerebellar slices were incubated in phosphate-free artificial cerebrospinal fluid (aCSF) containing ATP (25 or 100 μM) with or without POM-1. Aliquots of the solution were taken at timed intervals over 30 minutes, and the accumulation of inorganic phosphate was measured colorimetrically to determine the rate of ATP hydrolysis. [1]
To investigate the site of action in the ATP breakdown pathway, HPLC analysis was employed. Cerebellar slices were incubated with etheno-ATP (50 μM), and the breakdown products (etheno-ADP, etheno-AMP, etheno-adenosine) were separated and quantified using a C18 column with a potassium phosphate/methanol gradient. [1] |
| Animal Protocol |
For electrophysiology and biochemical assays, cerebellar slices (400 μm thick) were prepared from 21-28 day old male Wistar rats. Rats were killed by cervical dislocation and decapitated. Slices were cut in cold, high-Mg²⁺, low-Ca²⁺ aCSF and then stored in normal aCSF at room temperature before use. [1]
Hippocampal slices (400 μm thick) were prepared from 16-22 day old Sprague-Dawley rats of either sex using a similar method, with slicing performed in ice-cold, high-Mg²⁺ aCSF. [1] |
| References |
|
| Additional Infomation |
POM-1 (sodium polytungstate) is a polyoxometalate representing a new class of NTPDase inhibitors. It is more potent than the previous standard inhibitor ARL 67156. [1] Its inhibitory mechanism appears to be non-competitive or has a higher affinity for ATP, as its potency is less dependent on substrate concentration. [1] While POM-1 is an effective tool for inhibiting extracellular ATP metabolism in simplified systems such as brain slices, its application in intact tissues is limited by its significant off-target effects: POM-1 directly inhibits glutamatergic synaptic transmission, and this inhibition is independent of its effects on purinergic signaling pathways. [1]
|
| Molecular Formula |
3[O4W-2].9[O3W].6[NA+]
|
|---|---|
| Molecular Weight |
2967.9954
|
| Exact Mass |
2969.15
|
| CAS # |
12141-67-2
|
| PubChem CID |
3084108
|
| Appearance |
White to off-white solid powder
|
| Density |
3.1 g/cm3
|
| Index of Refraction |
n20/D 1.5555
|
| Hydrogen Bond Acceptor Count |
39
|
| Heavy Atom Count |
57
|
| Complexity |
124
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~16.74 mM)
DMSO : ~50 mg/mL (~16.74 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (0.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (33.49 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3369 mL | 1.6846 mL | 3.3693 mL | |
| 5 mM | 0.0674 mL | 0.3369 mL | 0.6739 mL | |
| 10 mM | 0.0337 mL | 0.1685 mL | 0.3369 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
